NextCompany

$53 Million Specialty, Retail, and Compounding Pharmacy in Florida

Florida 340B Pharmacy with $53 Million Revenue

On NextCompany since August 28, 2026 (today)

FL areaEstablished 2013
Financial summary
Asking price
$9,750,000
Gross revenue
$53,000,000
Cash flow (SDE)
N/A
EBITDA
$1,914,000

Figures come from the listing party and are not verified or guaranteed by NextCompany. Parts of this page are AI-generated and may contain errors. Verify everything before relying on it. See the Buyer Terms.

Business overview

A Florida 340B pharmacy dispenses specialty, retail, and compounding medications. It focuses on therapies for oncology, HIV, and multiple sclerosis. Proprietary software tracks patient compliance. Payer mix includes 97 percent Medicare and Medicaid. Revenue exceeded $52,800,000 in 2017 with $1,914,000 EBITDA. Owners assist with transition while staff remains.

Who is a good fit for this business

  • Buyers pursuing 340B pharmacies in Florida.
  • Investors open to specialty medication dispensing.
  • Acquirers who value staff continuity and owner transition help.

Details

Reason for selling
The current owners have decided to step away from the business to address personal issues.

Frequently Asked Questions

The pharmacy dispenses specialty, retail, and compounding medications. Therapies focus on oncology, HIV, and multiple sclerosis. It includes dermatology and transplant.

Proprietary software built on PioneerRX tracks the patient continuum. It ensures therapeutic compliance.

Revenue exceeded $52,800,000 in 2017. Adjusted EBITDA reached $1,914,000. The asking price is $9.75 million plus inventory.

Owners assist with transition. The Pharmacist-in-Charge and entire staff are expected to stay. The payer mix is 97 percent Medicare and Medicaid.

Similar businesses